Podcasts

Bacterial contaminants in cell cultures pose a significant threat to the biopharmaceutical safety. How do scientists detect these hard-to-spot pests?

On a quest to bring new a new hemophilia gene therapy to the clinic, one research team leapt over hurdle after hurdle to produce enough viral therapeutics to treat a large number of patients.

Biobanking unearths samples that have been long lost in the backs of freezers and scientific information buried in dusty notebooks to make ground breaking discoveries for human health.

Gosia Trynka, Group Leader at The Sanger Institute and Experimental Science Director at Open Targets, talks about the importance of cellular context for translating genomic and transcriptomic insights into actionable targets.

John Moffat, a senior scientist in Biochemical and Cellular Pharmacology at Genentech, discusses the target validation and prioritization opportunities revealed at the crossroads of target-focused and phenotypic profiling approaches.

Walter Kolch, co-founder and director of Systems Biology Ireland discusses the merits of a network approach to target validation and why probing clinical samples early is critical to increasing drug development success.

Mica Zaragoza, Consultant, Global Custom Manufacturing & OEM Solutions, Promega Corporation, discusses the company's standard and custom product development and consultative services associated with biotechnology and molecular biology research and drug discovery.

Dr. George Karlin-Neuman, Director of Scientific Affairs with the Bio-Rad Digital Biology Center in Pleasanton, California.

The costs of doing business (badly)

O2 Control in the Cell Culture Incubator with Carl Radosivech, Panasonic Healthcare Corporation of North America.